There has been considerable clinical evidence for the use of potassium binders in the management of hyperkalemia in patients with heart failure. The most recent study is the DIAMOND trial, and results were just presented at the American College of Cardiology 2022 meeting. So what does it mean to “enable” RAASi therapy, and how does this impact outcomes for our patients with heart failure? Join our experts as they discuss the value of these trial results and the body of clinical evidence for use of potassium binders in the management of hyperkalemia in patients with heart failure.

Rate

List

Get this podcast via API

From The Podcast

This CME series provides primary care professionals with the knowledge and skill sets needed to effectively provide standard-of-care medicine within the constraints of a busy office setting. Faculty therapeutic area experts address how to overcome barriers preventing optimal patient outcomes by improving guideline adherence, and optimizing practice performance in areas where guidelines are needed.

Join Podchaser to...

Rate podcasts and episodes
Follow podcasts and creators
Create podcast and episode lists
& much more

Do you host or manage this podcast?
Claim and edit this page to your liking.

Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More